Metandienone

Oral
Adjunct in senile and postmenopausal osteoporosis, Promote constructive anabolism of proteins

In men, prostate or breast carcinoma. Severe hepatic impairment. Hypercalcaemia, hypercalciuria. Pregnancy.

Lactation; CV disorders, renal/hepatic impairment, epilepsy, migraine, DM, conditions aggravated by fluid retention. Children. Monitor hepatic function.

Fluid and electrolyte retention; psychiatric effects; hypercalcaemia, impaired glucose tolerance. Men: Impotence, gynaecomastia, hirsutism, male-pattern baldness, acne, seborrhoea, oedema, cholestatic jaundice. Women: Amenorrhoea, menstrual irregularities. Children: Premature closure of epiphyses, stops linear growth; virilisation symptoms.
Potentially Fatal: Hepatotoxicity.

May enhance effects of antidiabetics, ciclosporin, levothyroxine, warfarin. Resistance to the effects of neuromuscular blockers may occur.

May interfere with glucose tolerance and thyroid function tests.

Description: Metandienone possesses anabolic, some androgenic and little progestogenic activity.

Anabolic Agents